This review summarizes the therapeutic dilemma and available data regarding anticoagulation for thromboembolic prophylaxis in pregnant women with cardiovascular disorders, especially mechanical heart valves.
Emphasizes persistent uncertainties in anticoagulation for pregnant women with mechanical valves; leaves open the need for dedicated prospective trials.
Clinical Development Phases I‐III Regulatory, Quality, Manufacturing Pregnancy‐associated thrombosis is an important cause of morbidity and mortality during pregnancy. All anticoagulation options are associated with risks and benefits. Thus, although anticoagulation therapy is an important component of the management of thrombotic complications in pregnancy, it is associated with fetal and maternal complications. Therefore, pregnancy poses a serious therapeutic dilemma for both physicians and their patients. This review summarizes the available data on anticoagulation therapy for thromboembolic prophylaxis in pregnant women focusing on cardiovascular disorders, especially on treatment strategy in pregnant women with mechanical heart valves.
No takes yet. Share an insight, caveat, or question.
Goland et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: